| 衛生福利部國家中醫藥研究所 |
2006 |
Cespitulactones A and B, new diterpenoids from Cespitularia taeniata
|
Shen, Ya-Ching; Ho, Ching-Jen; Kuo, Yao-Haur; Lin, Yun-Sheng |
| 國立臺灣大學 |
2010 |
Cespitulins a-D, Novel Diterpenoids from Taiwanese Cespitularia Taeniata
|
林玉麒; 沈雅敬; LIN, YU-CHI; SHEN, YA-CHING |
| 國立成功大學 |
2014-06 |
Cespitulones A and B, Cytotoxic Diterpenoids of a New Structure Class from the Soft Coral Cespitularia taeniata
|
Lin, Yu-Chi; Wang, Shih-Sheng; Chen, Chung-Hsiung; Kuo, Yao-Haur; Shen, Ya-Ching |
| 國立臺灣大學 |
2014 |
Cespitulones A and B, Cytotoxic Diterpenoids of a New Structure Class from the Soft Coral Cespitularia taeniata
|
Lin, Yu-Chi; Wang, Shih-Sheng; Chen, Chung-Hsiung; Kuo, Yao-Haur; Shen, Ya-Ching; 陳春雄; 沈雅敬 |
| 國立東華大學 |
2005 |
Cessation of chronic low-dosage L-NAME treatment may improve endurance performance in trained rats
|
Lin, Chia-Chih; Li, Jia-Yi; Su, Yi-Ting; Hsieh, Sandy S |
| 臺大學術典藏 |
2021-10-15T08:26:47Z |
Cessation of epithelial Bmp signaling switches the differentiation of crown epithelia to the root lineage in a β-catenin-dependent manner
|
Yang Z.; Hai B.; Qin L.; Ti X.; Shangguan L.; Zhao Y.; Wiggins L.; Liu Y.; Feng J.Q.; JULIA YU-FONG CHANG; Wang F.; Liu F. |
| 中山醫學大學 |
2021 |
Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation
|
Lai, CY; Yang, SS; Lee, SW; Tsai, HJ; Lee, TY |
| 臺北醫學大學 |
2008-02 |
Cetia® / 暢寧®錠
|
藥劑部 |
| 臺北醫學大學 |
2010-02 |
Cetirizine® / 勝克敏®內服水劑
|
藥劑部 |
| 高雄醫學大學 |
2006 |
CETP基因多型性和台灣第2型糖尿病患者冠心症之關聯性
|
謝明家;辛世杰;蕭政岳;田凱仁;許世傑;辛錫璋 |
| 東海大學 |
2009 |
Cetrarioid lichen genera and species in NE China
|
Lai, M.-J., Chen, X.-L., Qian, Z.-G., Xu, L., Anti, T. |
| 臺大學術典藏 |
2021-09-09T02:26:28Z |
Cette belle viande: Cézanne's bathers of the Impressionist years, 1872-1880
|
CHIAO-MEI LIU |
| 臺大學術典藏 |
2020-03-05T06:28:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Jau-Yu Liau;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; JAU-YU LIAU; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2018-09-10T15:21:53Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; YIH-LEONG CHANG |
| 臺大學術典藏 |
2018-09-10T15:23:10Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Jin-Tung Liang |
| 臺大學術典藏 |
2018-09-10T15:23:29Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
JAU-YU LIAU; Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H. |
| 臺大學術典藏 |
2018-09-10T15:25:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Ji-Shiang Hung |
| 臺大學術典藏 |
2020-02-25T05:15:25Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:23Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Yih-Leong Chang;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-06-16T07:53:31Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Liang-In Lin;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; LIANG-IN LIN; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-05T07:31:46Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Jia-Huei Tsai;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Yeh K.-H.; Cheng A.-L.; Chang Y.-L.; Lin L.-I.; Tseng L.-H.; JIA-HUEI TSAI; Liang J.-T.; Lin B.-R.; Hung J.-S. |
| 臺大學術典藏 |
2021-05-03T02:20:55Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Jin-Tung Liang;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; JIN-TUNG LIANG; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-05-07T02:46:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
YI-HSIN LIANG; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:50Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:29Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Kun-Huei Yeh; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
